Evidence map›Paper›PMID 30948648›Full record

ArticleCMAJ open

Impact of comprehensive hospice palliative care on end-of-life care: a propensity-score-matched retrospective observational study.

Michael S C Conlon, Joseph M Caswell, Andrew Knight, Barbara Ballantyne, Stacey A Santi, Margaret L Meigs, Craig C Earle, Mark Hartman

Abstract read
In one paragraph

Article in CMAJ open. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Michael S C ConlonEpidemiology, Outcomes and Evaluation Research (Conlon, Caswell, Santi, Meigs), Health Sciences North Research Institute; ICES North Satellite Site (Conlon, Caswell), Health Sciences North Research Institute; Northeast Cancer Centre (Knight, Ballantyne, Hartman), Health Sciences North, Sudbury, Ont.; Cancer Care Ontario (Hartman); Ontario Palliative Care Network (Knight, Ballantyne); Canadian Partnership Against Cancer (Earle), Toronto, Ont. mconlon@hsnri.ca.
Joseph M CaswellEpidemiology, Outcomes and Evaluation Research (Conlon, Caswell, Santi, Meigs), Health Sciences North Research Institute; ICES North Satellite Site (Conlon, Caswell), Health Sciences North Research Institute; Northeast Cancer Centre (Knight, Ballantyne, Hartman), Health Sciences North, Sudbury, Ont.; Cancer Care Ontario (Hartman); Ontario Palliative Care Network (Knight, Ballantyne); Canadian Partnership Against Cancer (Earle), Toronto, Ont.
Andrew KnightEpidemiology, Outcomes and Evaluation Research (Conlon, Caswell, Santi, Meigs), Health Sciences North Research Institute; ICES North Satellite Site (Conlon, Caswell), Health Sciences North Research Institute; Northeast Cancer Centre (Knight, Ballantyne, Hartman), Health Sciences North, Sudbury, Ont.; Cancer Care Ontario (Hartman); Ontario Palliative Care Network (Knight, Ballantyne); Canadian Partnership Against Cancer (Earle), Toronto, Ont.
Barbara BallantyneEpidemiology, Outcomes and Evaluation Research (Conlon, Caswell, Santi, Meigs), Health Sciences North Research Institute; ICES North Satellite Site (Conlon, Caswell), Health Sciences North Research Institute; Northeast Cancer Centre (Knight, Ballantyne, Hartman), Health Sciences North, Sudbury, Ont.; Cancer Care Ontario (Hartman); Ontario Palliative Care Network (Knight, Ballantyne); Canadian Partnership Against Cancer (Earle), Toronto, Ont.
Stacey A SantiEpidemiology, Outcomes and Evaluation Research (Conlon, Caswell, Santi, Meigs), Health Sciences North Research Institute; ICES North Satellite Site (Conlon, Caswell), Health Sciences North Research Institute; Northeast Cancer Centre (Knight, Ballantyne, Hartman), Health Sciences North, Sudbury, Ont.; Cancer Care Ontario (Hartman); Ontario Palliative Care Network (Knight, Ballantyne); Canadian Partnership Against Cancer (Earle), Toronto, Ont.
Margaret L MeigsEpidemiology, Outcomes and Evaluation Research (Conlon, Caswell, Santi, Meigs), Health Sciences North Research Institute; ICES North Satellite Site (Conlon, Caswell), Health Sciences North Research Institute; Northeast Cancer Centre (Knight, Ballantyne, Hartman), Health Sciences North, Sudbury, Ont.; Cancer Care Ontario (Hartman); Ontario Palliative Care Network (Knight, Ballantyne); Canadian Partnership Against Cancer (Earle), Toronto, Ont.
Craig C EarleEpidemiology, Outcomes and Evaluation Research (Conlon, Caswell, Santi, Meigs), Health Sciences North Research Institute; ICES North Satellite Site (Conlon, Caswell), Health Sciences North Research Institute; Northeast Cancer Centre (Knight, Ballantyne, Hartman), Health Sciences North, Sudbury, Ont.; Cancer Care Ontario (Hartman); Ontario Palliative Care Network (Knight, Ballantyne); Canadian Partnership Against Cancer (Earle), Toronto, Ont.
Mark HartmanEpidemiology, Outcomes and Evaluation Research (Conlon, Caswell, Santi, Meigs), Health Sciences North Research Institute; ICES North Satellite Site (Conlon, Caswell), Health Sciences North Research Institute; Northeast Cancer Centre (Knight, Ballantyne, Hartman), Health Sciences North, Sudbury, Ont.; Cancer Care Ontario (Hartman); Ontario Palliative Care Network (Knight, Ballantyne); Canadian Partnership Against Cancer (Earle), Toronto, Ont.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAccess to hospice palliative care may improve quality of life, reduce the use of potentially aggressive end-of-life care and allow for death to occur outside of an acute care hospital. The aim of this study was to examine the impact of an ambulatory hospice palliative care program on end-of-life care compared to care received by a matched control group of deceased patients.

methodsThis retrospective study included patients who received hospice palliative care through the Symptom Management Program in Sudbury, Ontario, during 2012-2015. Using linked administrative health records, we defined a propensity-matched control group and derived 4 previously defined variables associated with aggressive end-of-life care (chemotherapy received in the last 2 wk of life, > 1 emergency department visit within 30 d of death, > 1 hospital admission within 30 d of death and at least 1 intensive care unit admission within 30 d of death). We also examined place of death. We measured family/caregiver satisfaction with care 3 months after the patient's death using the FAMCARE questionnaire.

resultsOf 914 eligible decedents enrolled in the Symptom Management Program, 754 (82.5%) were matched. Receiving care through the program was protective for most measures of aggressive end-of-life care (absolute risk reduction [ARR] 12.73, 95% confidence interval [CI] 12.65-12.81 for any end-of-life care outcome) and death in an acute care setting (ARR 19.89, 95% CI 19.78-20.00). Of the 450 family caregivers invited to complete the FAMCARE questionnaire, 190 (42.2%) returned completed surveys; following data linkage and matching, 96 (21.3%) were available for analysis. Satisfaction with care received within the program appeared high (mean total score 85.72/100).

interpretationProvision of hospice palliative care through this ambulatory program was associated with lower use of aggressive end-of-life care and death outside of an acute care hospital. Improving access could be expected to provide positive benefits at the individual and system level.

Identifiers

PMID30948648
PMCPMC6450796

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.